Abstract
When geriatrician Thomas Perls treated his first centenarians in 1992, he expected to find them debilitated by illness and dementia. But he instead discovered that some extremely old individuals can escape Alzheimer's disease and other age-related disorders. In 1994 at Harvard Medical School, he started the New England Centenarian Study (NECS), a survey that has grown into an international investigation with data on 1000 centenarians from the United States, Canada, Germany, Japan, and Australia. Now based at the Boston University School of Medicine, the study has toppled several misconceptions about extremely old age and suggests a genetic basis to exceptional longevity. The work led to the founding of a biotech company called Centagenetix, which subsequently merged with Elixir Pharmaceuticals.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
